AI Helps Diagnose Post-COVID Lung Problems

A new computer-aided diagnostic tool developed by KAUST (King Abdullah University of Science & Technologym, Saudi Arabia) scientists could help overcome some of the challenges of monitoring lung health following viral infection.

Like other respiratory illnesses, COVID-19 can cause lasting harm to the lungs, but doctors have struggled to visualize this damage. Conventional chest scans do not reliably detect signs of lung scarring and other pulmonary abnormalities, which makes it difficult to track the health and recovery of people with persistent breathing problems and other post-COVID complications.

The new method developed by KAUST - known as Deep-Lung Parenchyma-Enhancing (DLPE) - overlays artificial intelligence algorithms on top of standard chest imaging data to reveal otherwise indiscernible visual features indicative of lung dysfunction.

Through DLPE augmentation, "radiologists can discover and analyze novel sub-visual lung lesions," says computer scientist and computational biologist Xin Gao. "Analysis of these lesions could then help explain patients’ respiratory symptoms," allowing for better disease management and treatment, he adds.

Gao and members of his Structural and Functional Bioinformatics Group and the Computational Bioscience Research Center created the tool, along with artificial intelligence researcher and current KAUST Provost Lawrence Carin and clinical collaborators from Harbin Medical University in China.

The method first eliminates any anatomical features not associated with the lung parenchyma; the tissues involved in gas exchange serve as the main sites of COVID-19 - induced damage. That means removing airways and blood vessels, and then enhancing the pictures of what is left behind to expose lesions that might be missed without the computer's help.

The researchers trained and validated their algorithms using computed tomography (CT) chest scans from thousands of people hospitalized with COVID-19 in China. They refined the method with input from expert radiologists and then applied DLPE in a prospective fashion for dozens of COVID-19 survivors with lung problems, all of whom had experienced severe disease requiring intensive care treatment.

In this way, Gao and his colleagues demonstrated that the tool could reveal signs of pulmonary fibrosis in COVID long-haulers, thus helping to account for shortness of breath, coughing and other lung troubles. A diagnosis, he suggests, that would be impossible with standard CT image analytics.

"With DLPE, for the first time, we proved that long-term CT lesions can explain such symptoms," he says. "Thus, treatments for fibrosis may be very effective at addressing the long-term respiratory complications of COVID-19."

Although the KAUST team developed DLPE primarily with post-COVID recovery in mind, they also tested the platform on chest scans taken from people with various other lung problems, including pneumonia, tuberculosis and lung cancer. The researchers showed how their tool could serve as a broad diagnostic aide for all lung diseases, empowering radiologists to, as Gao puts it, "see the unseen."

Zhou L, Meng X, Huang Y et al.
An interpretable deep learning workflow for discovering subvisual abnormalities in CT scans of COVID-19 inpatients and survivors.
Nat Mach Intell, 2022. doi: 10.1038/s42256-022-00483-7

Most Popular Now

The Future of Medicine is Data

At the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new...

Study Surveys Landscape of Apps Built on…

A study led by Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, is among the first to survey the current landscape of FHIR® apps, providing a snapshot of how...

New Computer Program 'Learns' to Identif…

Genetic mutations cause hundreds of unsolved and untreatable disorders. Among them, DNA mutations in a small percentage of cells, called mosaic mutations, are extremely difficult to detect because they exist...

Applications Open for SpinLab Accelerato…

The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the...

Bayer to Accelerate Drug Discovery with …

Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run...

Allscripts Announces Corporate Name Chan…

Allscripts Healthcare Solutions, Inc. announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand...

220M€ Investment in Testing and Experime…

To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI. Together...

AI Tool Developed to Predict Risk of Lun…

Lung cancer is the leading cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is recommended to screen people between 50 and...

Artificial Nerve Cells - Almost Like Bio…

Researchers at Linköping University (LiU), Sweden, have created an artificial organic neuron that closely mimics the characteristics of biological nerve cells. This artificial neuron can stimulate natural nerves, making it...

Bayer Acquires Blackford Analysis Ltd. B…

Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. The acquisition is part of Bayer's strategy to drive innovation in radiology, including...

For Shared Decision-Making, Telemedicine…

Telemedicine may be just as effective as in-person visits when it comes to shared decision-making and communication for patients undergoing a first-time surgery consultation, according to a study published as...

Veradigm Announces Strategic Investment …

Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced an investment in Holmusk, a global behavioral health real-world evidence and data analytics company, as part of Holmusk's $45 million...